Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Shilpa Medicare Ltd indicates a balanced stance on the stock, suggesting that investors should maintain their existing positions rather than aggressively buying or selling. This rating reflects a nuanced view of the company’s prospects, weighing both strengths and challenges across multiple parameters. The Mojo Score for the stock currently stands at 57.0, a notable improvement from the previous score of 43. This score reflects a moderate confidence level in the stock’s potential, signalling neither a strong buy nor a sell recommendation.
Quality Assessment
As of 29 May 2026, Shilpa Medicare’s quality grade is assessed as below average. This is primarily due to its long-term fundamental strength, which remains weak. The company’s average Return on Capital Employed (ROCE) over recent years is 5.44%, indicating modest efficiency in generating profits from its capital base. While the company has demonstrated steady growth in net sales at an annual rate of 11.30% and operating profit growth of 19.78% over the past five years, these figures suggest moderate expansion rather than robust outperformance. Investors should note that consistent profitability and capital efficiency are key drivers of quality, and Shilpa Medicare’s metrics indicate room for improvement in these areas.
Valuation Considerations
The valuation grade for Shilpa Medicare is currently classified as expensive. The company’s ROCE of 9.8 and an enterprise value to capital employed ratio of 3.2 suggest that the stock is priced at a premium relative to its capital efficiency. However, it is important to highlight that the stock trades at a discount compared to its peers’ average historical valuations, which may offer some cushion for investors. The price-to-earnings-to-growth (PEG) ratio stands at 0.4, signalling that despite the premium valuation, the company’s earnings growth prospects are attractive relative to its price. This valuation profile implies that while the stock is not cheap, it may still offer reasonable value given its growth trajectory.
Financial Trend and Recent Performance
Financially, Shilpa Medicare exhibits a very positive trend. The latest data as of 29 May 2026 shows a remarkable 99.09% growth in net profit, underscoring a strong earnings momentum. The company has declared positive results for 11 consecutive quarters, reflecting consistent operational performance. Key quarterly metrics include a highest-ever PBDIT of ₹119.71 crores and a PBT (excluding other income) of ₹93.75 crores. The half-yearly ROCE peaked at 10.52%, indicating improved capital utilisation in the recent period. Over the past year, the stock has delivered an 11.03% return, outperforming the broader BSE500 index in each of the last three annual periods. Year-to-date returns are even more impressive at 54.09%, with a three-month gain of 47.18%, signalling strong investor interest and positive market sentiment.
Technical Outlook
From a technical perspective, Shilpa Medicare is rated bullish. The stock’s price action over recent months supports this view, with a one-month gain of 22.45% and a six-month increase of 44.81%. The positive momentum is further reinforced by a modest daily gain of 0.57% on 29 May 2026. This bullish technical grade suggests that the stock is currently in an upward trend, which may attract momentum investors looking for short- to medium-term gains. However, technical strength should be considered alongside fundamental factors to form a comprehensive investment view.
Shareholding and Market Capitalisation
Shilpa Medicare is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. The majority of its shares are held by non-institutional investors, which can sometimes lead to higher volatility compared to stocks with strong institutional backing. Investors should be mindful of this when considering position sizing and risk management.
Summary for Investors
In summary, Shilpa Medicare Ltd’s 'Hold' rating reflects a stock with mixed attributes. While the company’s financial trend is very positive, with strong profit growth and consistent quarterly results, its quality metrics remain below average and valuation is on the expensive side. The bullish technical outlook adds a layer of optimism, but investors should weigh this against the company’s fundamental challenges and premium pricing. For those holding the stock, the current rating suggests maintaining positions while monitoring developments closely. Prospective investors may consider waiting for clearer signs of fundamental improvement or a more attractive valuation before initiating new positions.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Contextualising Returns and Market Performance
Looking at the stock’s returns in a broader market context, Shilpa Medicare has demonstrated resilience and outperformance. Its 11.03% return over the past year surpasses the BSE500 index, which has experienced more modest gains. The year-to-date return of 54.09% is particularly notable, reflecting strong investor confidence amid a challenging macroeconomic environment. This performance is supported by the company’s ability to sustain profit growth and deliver positive quarterly results consistently.
Investment Implications of the Mojo Score
The Mojo Score of 57.0 places Shilpa Medicare in the 'Hold' category, signalling a moderate risk-reward profile. This score is derived from a comprehensive analysis of quality, valuation, financial trend, and technical factors. Investors should interpret this rating as an indication to exercise caution, maintaining existing holdings while awaiting further clarity on the company’s fundamental trajectory. The score’s improvement from 43 to 57 since the last update on 06 May 2026 reflects progress but also highlights that the stock has not yet reached a level warranting a more bullish stance.
Sector and Industry Considerations
Operating within the Pharmaceuticals & Biotechnology sector, Shilpa Medicare faces sector-specific challenges such as regulatory scrutiny, pricing pressures, and competitive dynamics. While the company’s recent financial results are encouraging, investors should remain aware of these external factors that can impact future performance. The sector’s growth prospects remain robust globally, but individual company outcomes can vary significantly based on product pipelines, market access, and operational efficiency.
Conclusion
Shilpa Medicare Ltd’s current 'Hold' rating by MarketsMOJO reflects a balanced view of its investment merits and risks. The company’s strong recent profit growth and bullish technical indicators are tempered by below-average quality metrics and an expensive valuation. Investors should consider this rating as guidance to maintain existing positions with a watchful eye on upcoming financial results and market developments. The stock’s performance relative to its sector and peers will be critical in determining whether it can transition to a more favourable rating in the future.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
